Chord Therapeutics launches with USD 16 million Series A financing
Backed by Omega Funds to develop new oral treatments for rare autoimmune diseases
Financing for clinical trial of lead molecule for the treatment of neuromyelitis optica spectrum disorders
GENEVA, Switzerland, Oct. 13, 2020 -- (Healthcare Sales & Mar... Biopharmaceuticals, Venture Capital Chord Therapeutics, cladribine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | Brain | Clinical Trials | Neurology | Pharmaceuticals | Switzerland Health | Venture Capital